SEC Contract Filing

Filing Date: 2018-02-26

Document Content:
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>10
<FILENAME>exel20171231exhibit1046.htm
<DESCRIPTION>EXHIBIT 10.46
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
 <!-- Document created using Wdesk 1 -->
 <!-- Copyright 2018 Workiva -->
 <title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAE71E2383C097FE552F7B51B914AA1A4"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.46</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">THIRD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Third</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is entered into as of October 26, 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Third</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and between </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen Pharma SAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Licensee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#2e2e2e;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by Amendment No. 1, dated effective December 20, 2016, and Amendment No. 2 dated effective September 14, 2017 (together, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">License Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Parties desire to enter into this Third Amendment to update certain definitions and manufacturing responsibilities under the License Agreement, all on the terms and conditions set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:Calibri,sans-serif;font